Dilemmas on emicizumab in children with haemophilia A: A survey of strategies from PedNet centres.
Susanna RantaJayashree MotwaniJan BlatnyMartina BührlenManuel D CarcaoHervé ChambostCarmen EscuriolaKathelijn FischerMutlu Kartal-KaessMarloes de KovelTami LivnatChristoph MaleBeatrice NolanRoseline d'OironMartin OlivieriEster ZapotockaNadine G AnderssonChristoph KönigsPublished in: Haemophilia : the official journal of the World Federation of Hemophilia (2023)
Most centres choose to initiate prophylaxis with emicizumab before 12 months of age and without concomitant FVIII. In inhibitor patients, ITI is mostly given in addition to emicizumab, but there was no common practice on how to proceed after successful ITI.